For best experience enable Javascript.
Contact Us
Careers
Facebook
Instagram
Twitter
LinkedIn
Our Company
Who We Are
Leadership & Board
Patient Advocacy
Diversity, Equity, Inclusion & Belonging
Grant Programs
ISR Grants
Med Ed Grants
Contact Us
Careers
News
Our Science
Our Pipeline
Sparsentan for IgAN
Sparsentan for FSGS
Chenodeoxycholic Acid (CDCA) Program
Pegtibatinase
Alagille Syndrome Collaboration
Therapeutic Areas
IgA Nephropathy (IgAN)
Focal Segmental Glomerulosclerosis (FSGS)
Classical Homocystinuria (HCU)
Alagille Syndrome (ALGS)
Bile Acid Synthesis Disorders (BASD)
Cerebrotendinous Xanthomatosis (CTX)
Cystinuria
Peroxisome Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD)
Clinical Trials
Expanded Access
Diagnostic Testing Programs
Our Therapies
Rare Life
Investors & Media
Press Releases
Events & Presentations
Leadership & Board
Governance Documents
SEC Filings
Quarterly Results
Stock Information
Historic Stock Lookup
Analyst Coverage
Investor Q&As
Contact Us
NEWS
Home
▶
News
January 13, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2023
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 3, 2023
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 14, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2022
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 9, 2022
Travere Therapeutics to Present at Upcoming Investor Conferences
October 27, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 26, 2022
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 20, 2022
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
Page 1 of 8
1
2
3
4
5
6
7
8
›